The
Bubonic Plague bacterium is
commonly transmitted from rodent to human by the
oriental rat flea, Xenopsylla cheopis
(Figure 1). The flea is a rodent parasite and
human infection is accidental.
Figure 1.
Transmission of the Bubonic Plague bacteria.
From 11000 to 24000
unencapsulated bacteria are regurgitated from
the flea's midgut. Because of its low body
temperature, the bacillus is unable to develop a
capsule within the flea. The body temperature of
the flea is approximately 27°C, whereas the
human body temperature is 37°C - a more
desirable environment. The plague is caused by
Yersinia pestis, a Gram-negative
bacillus, belonging to the family
Enterobacteriaceae. Y. pestis is a
non-spore-forming, facultative anaerobe. They are
the only species of Yersinia that are
non-motile at room temperature. In addition,
Y. pestis is catalase-positive, oxidase-negative, urease-negative, and indole-negative
(Figure 2).
Figure 2.
Sheep blood agar plate of Yersinia
pestis bacteria. This was the appearance of the colonial growth
after 96 hours of incubation at 25ºC.
Virulence and Pathogenicity: The virulence factors of
Y. pestis are encoded by bacterial plasmids
(pCD1), rather than by the bacterial DNA. It
also hosts two other plasmid which are not
carried by other Yersinia species,
namely: pPCP1 and pMT1. pMT1 codes for
phospholipase D: this is important for the
ability of Y. pestis to be transmitted
by fleas. pPCP1 codes for a protease, PIa, which
activates plasminogen in human hosts and is an
important virulence factor for pneumonic plague.
pPCP1 and pMT1 along with a pathogenicity island
called HPI, encode several proteins for Y.
pestis pathogenesis. These virulence
factors are required for bacterial adhesion and
injection of proteins into the host cell,
injection of bacteria into the host cell, and
acquisition and binding of iron harvested from
red blood cells.
The unencapsulated bacilli
are phagocytosed. Those that are phagocytosed by
neutrophils are killed, but those phagocytosed
by macrophages are protected from destruction.
The protected bacilli multiply within
macrophages. The main goal of this bacteria is
to block the macrophages ability to produce
pro-inflammatory cytokines (like TNFα). After
three to five hours at 37°C, the bacilli produce
the F-1 capsular protein(See
Vaccination) . The anti-phagocytotic capsule
prevents further phagocytosis. Bacteria then
spread to regional lymph nodes. Here they
continue to rapidly multiply, causing swelling.
Virulence factors,
transcribed from the bacteria plasmids, are
translocated to the host cells. These include
the V protein and YOPs (Yersinia outer
proteins). In fact, Y. pestis has
several virulence factors: attachment to host
cells occurs via YadA “adhesin”; YadA also
inhibits Complement activation. YopJ inhibits
macrophage activation and pro-inflammatory
cytokine production. YopH inhibits disrupts
cytoskeleton and so inhibits phagocytosis
(Figure 3). Once infected, cell death soon
follows. Bacteria spread to regional lymph
nodes. The swollen node is called a bubo,
hence the term bubonic plague. Progressive
infection spreads to nearly every organ of the
body. Without antibiotic treatment, death may
result within two to six days.
Figure 3.
Some of the molecular factors involved in
pathogenesis of Yersinia pestis
infection. Click to enlarge.
Clinical Infections:The three types of infection
caused by Y. pestis are
bubonic,septicemic,
and pneumonic
plague.
(1) Pneumonic plaque is the
least common but most dangerous form of Y.
pestis. The primary complication is due to
inhalation of infectious respiratory droplets
expelled from a human or animal that has plague
pneumonia. However, it develops more typically
due to a secondary complication of septicemic
plague. It’s characterized by an infection of
the lungs. Signs of pneumonic plague include:
Severe pneumonia
High fever
Difficulty
breathing/shortness of breath
Coughing up blood
Lethargy
2) Septicemic plague occurs
when Y. pestis invades and continues to
multiply in the bloodstream; it can develop
without detectable lymph node swelling and pain.
Patients who do not receive adequate treatment
within 18 hours after onset of respiratory
symptoms are unlikely to survive. It’s
characterized by an infection in the
bloodstream. Signs of septicemic plague include:
General lack of energy
High fever
Shock
Delirium
Hypotension
3) As discussed earlier, the
Bubonic plague is the most common disease caused
by Y. pestis. Signs of bubonic plague
are seen within two to six days of being bitten
by an infected
flea. Swollen, painful lymph nodes are caused by
the
multiplication of bacteria. Outbreaks of this
plague caused large
percentages of the population to die in the
past, but currently, it’s only a serious problem
in undeveloped countries where sanitary
conditions are poor. It’s characterized by an
infection in the lymph nodes. Signs of bubonic
plague include:
(1) Flea bite
(2) Contact with an infected host
(3) Contact with sick animals or rodents
(4) Residence in an endemic area of plague
(5) Presence of a food source for rodents in the
immediate vicinity of the home
(6) Camping, hiking, hunting, fishing
(7) Occupational exposure
(8) Direct handling or inhalation of
contaminated tissue/tissue fluids
Control: Diagnosis must be made
quickly due to fast progression of the disease
and the high mortality rate.
(1) Eliminating food and shelter for rodents in
and near homes
(2) Avoiding direct contact with sick or dead
rodents and their nests.
(3) Handling severe ill cats with extreme
caution
(4) Hunters should wear gloves when handling
dead animals
(5) Treating domestic dogs and cats weekly with
appropriate insecticides
(6) Using insect repellants containing
N,N-diethyl-m-toluamide on skin when
Y. pestis is detected.
Vaccination: The Fraction 1 (F-1) capsular
antigen is the most immunogenic fraction in a
Y. pestis bacilli preparation. Thus, a
surface antigen is an excellent plague vaccine
strategy. Early F-1 vaccine preparations induced
antibodies and conferred protection. But while
initial inoculations gave minimal side effects,
booster inoculations produced sever
hypersensitivity reactions (allergic reactions).
This may have been due to other cell
contaminants within the vaccine preparation.
Therefore, the early F-1 vaccine, difficult and
expensive to prepare, was discontinued.
A new vaccine preparation,
consisting of genetically engineered F-1 and V
proteins, is now under development. It promises
to be the most effective to date, producing
minimal side-effects.